Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
_256_384.jpg)
The Vice President also highlighted the importance of preventive healthcare and fitness
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
We are achieving the target of developed India by making our young children healthy today
The fast pace of construction of AIIMS Jammu whose foundation stone laying to inauguration took only 5 years highlights the commitment of the Government
The project aims at screening the general health condition of the students enrolled in classes 6th to 12th.
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The agreement sets terms under which POC will manufacture the product or receive royalties
Subscribe To Our Newsletter & Stay Updated
